Packaging error leads to birth control pill recall in US

May 30, 2018

Allergan is voluntarily recalling packs of its birth control pills in the U.S. because of a packaging error with placebos, increasing the possibility of unintended pregnancy.

The company says four placebo pills were placed out of order in the Taytulla packs. Allergan says the first four days of therapy had four non-hormonal placebo capsules instead of active capsules.

The recall involves lot 5620706, which expires in May 2019. Consumers who have those should arrange to return them to their physicians.

Consumers with questions about the recall are being asked to contact Allergan at 800-678-1605, Monday through Friday.

Explore further: Women's wellness: Birth control pill benefits, risks and choices

Related Stories

Women's wellness: Birth control pill benefits, risks and choices

April 23, 2018
The birth control pill is surrounded by misinformation. Get the facts on common concerns and questions about taking the pill. If you take the birth control pill (oral contraceptive), you're probably happy with its convenience ...

Pfizer recalls 1 million packets of US birth control pills

February 1, 2012
US pharmaceutical giant Pfizer on Wednesday recalled one million packets of birth control pills over a packaging error that could put women at risk of unintended pregnancy.

US recalls India-made birth control pills

February 27, 2012
A batch of birth control pills manufactured in India for US distribution has been recalled due to a packaging error that could make the pills ineffective, US health authorities said on Monday.

Allergan tells shareholders to reject Valeant deal

June 23, 2014
Allergan, the maker of Botox, said Monday that Valeant Pharmaceuticals' hostile takeover bid for the company is "grossly inadequate" and that shareholders should reject it.

Valeant launches hostile $53B bid for Allergan

June 18, 2014
Valeant Pharmaceuticals said Wednesday it has launched a tender offer for Allergan, the maker of Botox, taking its hostile bid directly to shareholders.

Teva expect to close $40.5B Allergan generic deal next week

July 27, 2016
Israeli drugmaker Teva, the largest generic drug company in the world, said Wednesday it expects to complete its $40.5 billion purchase of the generic drug business of competitor Allergan next week after federal regulators ...

Recommended for you

Medicating distress: Risky sedative prescriptions for older adults vary widely

October 18, 2018
Despite years of warnings that older adults shouldn't take sedative drugs that put them at risk of injury and death, a new study reveals how many primary care doctors are still prescribing them, how often, and exactly where.

Medical management of opioid-induced constipation differs from other forms of condition

October 17, 2018
Traditional laxatives are recommended as first-line agents to treat patients with a confirmed diagnosis of opioid-induced constipation (OIC), according to a new guideline from the American Gastroenterological Association ...

Research assesses geographic distribution of new antibiotics following market introduction

October 16, 2018
There is a growing need for new antibiotics to help combat the looming threat of antimicrobial resistance. According to a new study conducted by researchers at the Center for Disease Dynamics, Economics & Policy (CDDEP) with ...

Health insurer policies may discourage use of non-opioid alternatives for lower back pain

October 5, 2018
Public and private health insurance policies in the U.S. are missing important opportunities to encourage the use of physical therapy, psychological counseling and other non-drug alternatives to opioid medication for treating ...

Opioid overdoses, depression linked

October 3, 2018
The link between mental health disorders and substance abuse is well-documented. Nearly one in 12 adults in the U.S is depressed, and opioid-related deaths are skyrocketing. As these numbers continue to climb, some mental ...

Do price spikes on some generic drugs indicate problems in the market?

October 1, 2018
A new USC study reports that sudden price spikes for some generic drugs—such as the recently reported increases of a decades-old generic heart medication and an antibiotic—are becoming more common.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.